Serum Interleukin-6 Levels as a Prognostic Marker in Patients With Sepsis

Abstract

Interleukin-6 (IL-6) is one of the earliest and most abundant cytokines to rise in the blood of patients with sepsis, and many studies since the late 1980s have asked whether a single serum measurement can tell clinicians who is likely to do badly. This narrative review examines that question using published work on the biology of IL-6, the kinetics of the host response, and the design and reporting of prognostic marker studies. It reports no new data and no local cohort. Higher circulating IL-6 has repeatedly been associated with greater severity and with death, and the association is biologically coherent, because the cytokine is produced downstream of the first inflammatory signals and tracks the size of the insult. Yet the same literature shows why the marker has not become a bedside standard: concentrations change within hours, differ between assays and populations, overlap widely between survivors and non-survivors, and add uncertain value once severity scores are already known. Thresholds are rarely validated outside the cohort that produced them. Evidence that IL-6 can guide treatment is thinner still, and it is strongest where it is used to select patients with a hyperinflammatory picture instead of to predict outcome. The review concludes that IL-6 is a useful indicator of host response intensity, a modest prognostic aid at best when used alone, and a candidate for better-designed studies that report timing, calibration and added value over existing scores.